FD-501(FD-501) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

感染

在研适应症-

非在研适应症

细菌感染

原研机构

Gifu University

在研机构-

非在研机构

Gifu University

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 FD-501 相关的临床结果

登录后查看更多信息

100 项与 FD-501 相关的转化医学

登录后查看更多信息

100 项与 FD-501 相关的专利（医药）

登录后查看更多信息

1

项与 FD-501 相关的文献（医药）

1996-03-01·The Japanese journal of antibiotics

[In vitro and in vivo antibacterial activities of a new quinolone derivative, FD501].

Article

作者: Tahara, Y ; Maebashi, K ; Imamori, K ; Asaoka, T ; Matsumoto, M ; Matsuda, H

FD501 is a newly synthesized quinolone derivative with aminoazepine group at the C-7 position. The in vitro and in vivo antibacterial activities of FD501 were investigated comparing with those of norfloxacin, ofloxacin, ciprofloxacin and sparfloxacin. The in vitro antibacterial activities of FD501 against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus, were equal to or higher than those of other quinolones. But its activities against Gram-negative bacteria were equal to or lower than those of other quinolones. Minimum inhibitory concentrations of FD501 against Gram-positive bacteria were similar to that of sparfloxacin. The bactericidal activity may be due to the inhibition of the DNA super-coiling activity of DNA gyrase. The area under the serum concentration-time curve of FD501 in rats following oral administration was larger than norfloxacin and ciprofloxacin and smaller than those of ofloxacin and sparfloxacin.

100 项与 FD-501 相关的药物交易

登录后查看更多信息